Costotransverse Foramen BlockNCT07367581
Costotransverse Foramen Block Versus Thoracic Paravertebral Block in Thoracotomy for Lung Cancer
A study testing Costotransverse foramen block and Thoracic paravertebral plane block in people with Costotransverse Foramen Block and Thoracic Paravertebral Block, run by National Cancer Institute, Egypt at 1 site in Egypt.
Trial summary
This study aims to compare the costotransverse foramen block (CTFB) with thoracic paravertebral block (TPVB) in patients undergoing thoracotomy for lung cancer. Read more about this study
- Who is it for?
- Ages 18 to 65 years
- Conditions the study is for
- Costotransverse Foramen Block, Thoracic Paravertebral Block, Thoracotomy
- What is being tested?
- Costotransverse foramen block and Thoracic paravertebral plane block
- Type of treatment
- Injection or infusion
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 70 participants
- Where
- 1 siteEgypt
- Study dates
- 24 Jan 2026to 1 Jun 2026
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 65 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Age > 18 years and ≤ 65 years old.
- American Society of Anesthesiologists (ASA) physical status II-III.
- Body mass index 18-35 kg/m2.
- Patients scheduled for thoracotomies for lung cancer.
Who cannot join
- Patient refusal.
- History of sensitivity to local anesthetics.
- History of psychological disorders.
- Contraindication to regional anesthesia, e.g., local sepsis, pre-existing peripheral neuropathies, and coagulopathy.
- Severe respiratory, cardiac, hepatic, or renal disease.
- Morbid obesity.
- Uncooperative patients.
- Patients on chronic pain therapy.
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
Egypt1 site, 1 recruiting
- Recruiting
Cairo University
Cairo, 12613
Mai M Elrawas, MD, 00201222177242, mai.elrawas@nci.cu.edu.eg
About this study
Official title: Costotransverse Foramen Block Versus Thoracic Paravertebral Block in Thoracotomy for Lung Cancer: A Randomized Controlled Trial
This study aims to compare the costotransverse foramen block (CTFB) with thoracic paravertebral block (TPVB) in patients undergoing thoracotomy for lung cancer.
Read the detailed description
Thoracotomy is known to be one of the most painful surgeries. Managing post-thoracotomy pain is a major clinical challenge, as about 75% of patients report moderate to severe pain afterward.
Various regional and central analgesia techniques, such as thoracic epidural analgesia (TEA), thoracic paravertebral block (TPVB), and erector spinae plane block (ESPB), are employed in a multimodal approach. Although TEA has traditionally been considered the gold standard for thoracotomy pain control, concerns about its side effects have prompted the exploration of alternatives.
The costotransverse foramen block (CTFB), a recently introduced technique, has been examined in both cadaveric and case studies.
- Being tested
- Costotransverse foramen block, Thoracic paravertebral plane block
- Medical subject headings
- Lung Neoplasms
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Costotransverse foramen blockOther
Patients will receive an ipsilateral ultrasound-guided costotransverse foramen block with injection of 20 ml bupivacaine 0.25%.
Thoracic paravertebral plane blockOther
Patients will receive an ipsilateral ultrasound-guided thoracic paravertebral plane block with injection of 20 ml bupivacaine 0.25%.
| Study group | Role | What they receive |
|---|---|---|
| CTFB Group | Experimental | Patients will receive an ipsilateral ultrasound-guided costotransverse foramen block with injection of 20 ml bupivacaine 0.25%. Receives: Other: Costotransverse foramen block |
| TPVB Group | Experimental | Patients will receive an ipsilateral ultrasound-guided thoracic paravertebral plane block with injection of 20 ml bupivacaine 0.25%. Receives: Other: Thoracic paravertebral plane block |
What is being measured
The primary outcome is the main question the study is designed to answer.
Total morphine consumption
If the visual analog scale (VAS) is ≥ 4, rescue analgesics will be administered in the form of a 4 mg bolus of morphine.
Measured: 24 hours postoperatively
Secondary outcomes (7)
Duration of analgesia
Duration of analgesia will be recorded from the end of surgery till first dose of morphine administrated.
Measured: 24 hours postoperatively
Degree of pain
Each patient will be instructed about postoperative pain assessment with the visual analog scale (VAS). VAS (0 represents "no pain" while 10 represents "the worst pain imaginable"). VAS will be recorded in post-anesthesia care unit (PACU) and after 1, 6, 12, 24 \& 48 hours postoperatively
Measured: 48 hours postoperatively
Intraoperative fentanyl consumption
Intraoperative fentanyl consumption will be recorded.
Measured: Intraoperatively
Mean arterial blood pressure
Mean arterial blood pressure will be recorded before induction of general anesthesia to be defined as the baseline reading. Another reading will be noted immediately before surgical incision and at 20-minute intervals intraoperatively, and then hourly for the next 4 hours postoperatively.
Measured: 4 hours postoperatively
Heart rate
Heart rate will be recorded before induction of general anesthesia to be defined as the baseline reading. Another reading will be noted immediately before surgical incision and at 20-minute intervals intraoperatively, and then hourly for the next 4 hours postoperatively.
Measured: 4 hours postoperatively
Incidence of block-related side effects
Incidence of block-related side effects such as unexpected epidural anesthesia, pneumothorax, total spinal anesthesia, or local anesthetic intoxication will be recorded.
Measured: 4 hours postoperatively
Incidence of side effects
Incidence of side effects such as postoperative nausea and vomiting, drowsiness, or dyspnea will be recorded.
Measured: 4 hours postoperatively
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted26 Jan 2026
- Study start24 Jan 2026
- Primary completion1 Jun 2026 (estimated)
- Study completion1 Jun 2026 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Costotransverse Foramen BlockStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Double blind
- Who is masked
- Participant, Outcomes assessor
- Enrolment
- 70 participants (estimated)
Sponsor and investigators
- Lead sponsor
- National Cancer Institute, Egypt
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Mai Mohamed El Rawas, National Cancer Institute, Egypt
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07367581
- Sponsor's protocol ID
- AP2512-501-141-205
- Status last verified
- Jan 2026
- First submitted
- 17 Jan 2026
- Last updated
- 27 Jan 2026
- Results posted
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Yes: The data will be available upon a reasonable request from the corresponding author after the end of study for one year.
Study at a glance
From the registry record, last updated by the sponsor on 27 Jan 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Costotransverse Foramen Block Versus Thoracic Paravertebral Block in Thoracotomy for Lung Cancer: A Randomized Controlled Trial
- ClinicalTrials.gov ID
- NCT07367581
- Acronym / sponsor ID
- AP2512-501-141-205
- Study type
- Interventional
- Recruitment status
- Recruiting
- Enrolment
- 70 participants (estimated)
- Lead sponsor
- National Cancer Institute, EgyptUniversity, hospital or other
- Study start
- 24 Jan 2026 (actual)
- Primary completion
- 1 Jun 2026 (estimated)
- Study completion
- 1 Jun 2026 (estimated)
- First posted
- 26 Jan 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This study aims to compare the costotransverse foramen block (CTFB) with thoracic paravertebral block (TPVB) in patients undergoing thoracotomy for lung cancer.
Detailed description
Thoracotomy is known to be one of the most painful surgeries. Managing post-thoracotomy pain is a major clinical challenge, as about 75% of patients report moderate to severe pain afterward.
Various regional and central analgesia techniques, such as thoracic epidural analgesia (TEA), thoracic paravertebral block (TPVB), and erector spinae plane block (ESPB), are employed in a multimodal approach. Although TEA has traditionally been considered the gold standard for thoracotomy pain control, concerns about its side effects have prompted the exploration of alternatives.
The costotransverse foramen block (CTFB), a recently introduced technique, has been examined in both cadaveric and case studies.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Double blind (participant, outcomes assessor)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| CTFB Group | Experimental | Other: Costotransverse foramen blockPatients will receive an ipsilateral ultrasound-guided costotransverse foramen block with injection of 20 ml bupivacaine 0.25%. |
| TPVB Group | Experimental | Other: Thoracic paravertebral plane blockPatients will receive an ipsilateral ultrasound-guided thoracic paravertebral plane block with injection of 20 ml bupivacaine 0.25%. |
Who may qualify
- Ages
- 18 to 65 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (4 listed)
- Age > 18 years and ≤ 65 years old.
- American Society of Anesthesiologists (ASA) physical status II-III.
- Body mass index 18-35 kg/m2.
- Patients scheduled for thoracotomies for lung cancer.
Key exclusion criteria (8 listed)
- Patient refusal.
- History of sensitivity to local anesthetics.
- History of psychological disorders.
- Contraindication to regional anesthesia, e.g., local sepsis, pre-existing peripheral neuropathies, and coagulopathy.
- Severe respiratory, cardiac, hepatic, or renal disease.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Costotransverse foramen blockPatients will receive an ipsilateral ultrasound-guided costotransverse foramen block with injection of 20 ml bupivacaine 0.25%. | Other | CTFB Group |
| Thoracic paravertebral plane blockPatients will receive an ipsilateral ultrasound-guided thoracic paravertebral plane block with injection of 20 ml bupivacaine 0.25%. | Other | TPVB Group |
Primary outcome
Total morphine consumption
Time frame: 24 hours postoperatively
If the visual analog scale (VAS) is ≥ 4, rescue analgesics will be administered in the form of a 4 mg bolus of morphine.
7 secondary outcomes
Duration of analgesia
Time frame: 24 hours postoperatively
Degree of pain
Time frame: 48 hours postoperatively
Intraoperative fentanyl consumption
Time frame: Intraoperatively
Mean arterial blood pressure
Time frame: 4 hours postoperatively
Heart rate
Time frame: 4 hours postoperatively
Incidence of block-related side effects
Time frame: 4 hours postoperatively
Incidence of side effects
Time frame: 4 hours postoperatively
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 27 Jan 2026.
- Individual participant dataSharing planned: Yes. The data will be available upon a reasonable request from the corresponding author after the end of study for one year.
Related trials for Costotransverse Foramen Block
Recruiting
Costotransverse Foramen Block With Erector Spinae Plane Block in Modified Radical Mastectomy
Costotransverse Foramen Block, Erector Spinae Plane Block
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Costotransverse foramen block and Thoracic paravertebral plane block in people with Costotransverse Foramen Block and Thoracic Paravertebral Block, run by National Cancer Institute, Egypt at 1 site in Egypt.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 4 inclusion and 8 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 27 Jan 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Egypt. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Mai M Elrawas, MD (00201222177242, mai.elrawas@nci.cu.edu.eg), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Total morphine consumption (time frame: 24 hours postoperatively). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 27 Jan 2026; AzTrials last refreshed its copy on 7 Nov 2026.